Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Fuse Science Set to Redefine $3.0 Billion Patch Market with Roll-On Application Technology

October 23, 2012

MIAMI LAKES, Fla., Oct. 23, 2012 /PRNewswire/ — Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com), an innovative company that possesses proprietary delivery technology set to redefine how consumers receive energy, medicines, vitamins and minerals, today provides further insight into the numerous potential applications of their technology arising from their most recent scientific testing research results.

The conclusions of the research documented that the Company can deliver a wide range of compounds successfully through the epidermis in a simple roll-on application. This proprietary patchless delivery technology represents what the Company believes to be a major paradigm shift in the $3.0 billion dollar global patch market, which is growing at approximately 12% annually. Fuse believes that the ability to eliminate the need for a consumer or patient to wear a patch on the skin for extended compound delivery eliminates the frustration experienced by many consumers in having to wear a patch.

“These science results indicate that Fuse Science possesses capabilities to significantly enhance delivery and convenience with the application of our proprietary technology,” said Jeanne Hebert, Fuse Science, Vice President of Marketing and Clinical Research. “Being able to provide effective therapy, without requiring the patient to wear a patch throughout the day, is of major benefit to the consumer. Our previously announced licensing and M&A efforts coordinated by Atlas Advisors (www.atlasadvisors.com) are designed to specifically enable structured talks with the leading manufacturers in the growing $3.0 billion patch industry.”

Many of these compounds researched by Fuse Science relate directly to the patch market and the Company believes represent several new delivery opportunities. Estradiol, which is a very common estrogen replacement therapy delivered in patch form, was specifically researched documenting delivery through the epidermis in a roll-on application. Some of the other current leading transdermal delivery-based products are Fentanyl for pain management, Clonidine for high blood pressure, Nitroglycerine for chest pain, Lidocaine for nerve pain related to shingles, Nicotine, Testosterone, and the Ethinyl Estradiol and Norelgestromin combination to address pregnancy prevention. It is the Company’s belief that it can successfully deliver each of the stated compounds in roll-on form through their proprietary technology.

    For more information:          To schedule an interview:
    Fuse Science, Inc.             Gus DeQuesada
    Investor Relations             Michelsen Advertising
    Direct: (305) 503-3873, Ext. 2 C-305-733-1410 / 786-488-7138
    Email: ir@fusescience.com      prnews@michelsenadvertising.com

About Fuse Science, Inc.
Fuse Science, Inc. (OTCQB: DROP) is an innovative holding company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly either through a topical gel roll-on or alternatively in a concentrated “DROP” form that is simply applied under the tongue. Fuse Science’s technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement
Certain statements and information included in this release may constitute “forward-looking statements” as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management’s projections, estimates and expectations is contained in the Company’s SEC filings which can be found at www.sec.gov. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

SOURCE Fuse Science, Inc.


Source: PR Newswire